- Home
- SFWL vs PLRX Comparison
SFWL vs PLRX Comparison
Compare SFWL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFWL | PLRX |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.6M | 81.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SFWL | PLRX |
|---|---|---|
| Price | $0.98 | $1.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 6.0K | ★ 502.8K |
| Earning Date | 03-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.09 |
| 52 Week High | $1.29 | $1.95 |
Technical Indicators
Market Signals| Indicator | SFWL | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 49.71 |
| Support Level | $0.92 | $1.12 |
| Resistance Level | $1.00 | $1.39 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 50.06 | 62.58 |
Price Performance
Historical ComparisonAbout SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.